Treatment Options for Triple-Class Refractory Multiple Myeloma

Publication date: Available online 9 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Joseph MikhaelAbstractThe advent of new, more effective, and less toxic therapies has revolutionized the management of multiple myeloma in the past decade. Despite the availability of new treatments, the majority of patients with multiple myeloma will become refractory to the therapies that currently comprise the hematologic standard of care for the malignancy: proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. Moreover, in recent years, a new subset of patients refractory to all 3 of these agents has emerged. This population, in which a clear treatment paradigm remains undefined, is characterized by poor survival outcomes. Current approaches to the treatment of triple-class refractory disease are limited, and include conventional chemotherapy, salvage autologous stem cell transplantation, and recycling prior regimens, each of which have generally short-lived efficacy. It is anticipated that additional agents will be available for triple refractory disease in the near future, namely selinexor, chimeric antigen receptor T cell therapy, and next-generation monoclonal antibodies. The development and further refinement of novel treatments for this subset of patients in the coming years should be considered a key clinical and research priority.

Source: Clinical Lymphoma Myeloma and Leukemia - October 10, 2019 Category: Cancer & Oncology Source Type: research